The Use of Medications for Cognitive Enhancement

Author:

Pryse-Phillips William,Sternberg Shelley,Rochon Paula,Naglie Gary,Strong Howard,Feightner John

Abstract

Objective:To provide Canadian physicians and allied health care professionals with the evidence they need to help them make treatment decisions in the management of patients with Alzheimer’s disease or other dementias.Options:The full range and quality of diagnostic and therapeutic modalities available to Canadian physicians for the management of dementia.Outcomes:Improvement in the treatment of dementias, leading to reduced suffering, increased functional capacity and decreased economic burden.Evidence and values:The creation of these evidence-based consensus statements involved literature reviews of the subject by the authors; comparison of alternative clinical pathways and description of the methods whereby published data were analyzed; definition of the level of evidence for data in each case; evaluation and revision in a conference setting (involving primary care physicians, neurologists, psychiatrists, geriatricians, psychologists, consumers and other interested parties); insertion of tables showing key variables and data from various studies and tables of data with recommendations; and reassessment by all authors.Benefits, harms, and costs:A rational plan for the therapy of dementias is likely to lead to substantial benefits in both human and economic terms.Recommendations:Treatment decisions should be made taking into account the severity or stage of the disease, the availability of caregivers, the presence of disease affecting other bodily systems and the ability of the subject to pay the cost of the medications. Donepezil is considered to have positive effects upon certain tests of neuropsychological function and may produce some improvement in Alzheimer’s disease of mild to moderate severity as measured by rating scales. Its ability to improve quality of life remains uncertain. No other drug treatments* (apart from symptomatic therapies) are at present approved for the treatment of Alzheimer’s disease.Validation:These recommendations were created by a writing committee, evaluated and revised at a consensus conference and further reviewed and revised by the writing committee prior to publication.

Publisher

Cambridge University Press (CUP)

Subject

Neurology (clinical),Neurology,General Medicine

Reference67 articles.

1. 4-Aminopyridine in the treatment of alzheimer's disease

2. Effectiveness and Safety of Velnacrine for the Treatment of Alzheimer's Disease

3. Oral 5’-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a double-blind multicentre study;Passeri;Aging,1938

4. Efficacy of Xantinolnicotinate in Patients with Dementia

5. Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type;Bergamasco;Funct Neurol,1994

Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Development of a Brief Cognitive Screen for Mild Cognitive Impairment and Neurocognitive Disorder;Aging, Neuropsychology, and Cognition;2005-12

2. Canadian Outcomes Study in Dementia: Study Methods and Patient Characteristics;The Canadian Journal of Psychiatry;2004-07

3. Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis;BMC Geriatrics;2003-12

4. Cognition Enhancers;Burger's Medicinal Chemistry and Drug Discovery;2003-01-15

5. Current Awareness;International Journal of Geriatric Psychiatry;2001

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3